

11th September 2013

lan Craig National Stock Exchange of Australia Level 34 50 Bridge St SYDNEY NSW 2000

ian.craig@nsxa,com,au

Dear Ian

Re Application For Listing - IQX Ltd

Further to the lodgement of the attached prospectus for IQX Ltd on 6th September 2013 with ASIC, we would like to formally apply for listing with the NSX

The details required as per Appendix 1 are as follows:

1. General

- (1) The name of the applicant is IQX Ltd (A.C.N 155 518 380) incorporated on 6th February 2012.
- (2) N/A
- (3) The Registered Office is: C/- Economos Chartered Accountants Level P1 500 George St SYDNEY NSW 2000
- (4) We formally request listing of the company's fully paid ordinary shares. These ordinary shares have the usual rights to attend general meetings, vote, participate in dividends, participate in distribution of capital in winding up as conferred by the Corporations Act 2001.
- (5) The securities are planned to be brought to listing via a planned IPO, which includes:

- Existing Shares: 80,000,000

- Shares under the Prospectus: 32,500,000 Shares at Maximum or subject to subscription as per the following timetable:

Date Prospectus filed with ASIC

Applications open

Applications close

Dispatch of transaction statements

Planned listing date

6th September 2013
13th September 2013
15th November 2013
22nd November 2013

- (6) The net assets as per the 31 march accounts are \$696,000 before the IPO
- (7) The estimated proceeds from the issue will be to a maximum of \$6,500,000 (less approximately \$300,000 in listing fees). The capital will be used to fund the proposed business of investment in the Life Science sector.



(8) N/A

2. Share Capital & Ownership

(1)

Class Of Share	Ordinary Shares
Number Issued	80,000,000
Voting Rights	Entitled to vote at General Meetings
Amount of Fully Paid Up Shares	Total \$2,000
Shareholdings By Director & Officers	
Kosmas Dimitriou	NIL
Peter Simpson	NIL
Anthony Panoyan	NIL
John Stratilas	1,600,000
Alex Dimos	13,990
Spiro Sakiris (Chief Operations Officer)	1,639,530

(Grouped by Common Controller Based Upon Latest Information Supplied To Company By Shareholders)			
Name	Number	%	
Ruminate Investments Pty Ltd	15,800,000	19.75%	
TTS Two Investments Pty Ltd ATF TTS Discretionary Trust	4,500,000	5.63%	
	20,300,000	25.38%	
Life Science Investments Pty Ltd ATF Life Science Super Fund	6,000,000	7.50%	
Zero Hedge Investments Pty Ltd ATF Zero Hedge Investments Trust	5,550,000	6.94%	
Biotechnology Holdings Pty Ltd ATF Biotechnology Trust	4,261,112	5.33%	
	15,811,112	19.76%	
Abiogenises Pty Ltd	15,600,000	19.50%	
Agparaskevi Pty Ltd ATF Agparaekevi Trust	8,000,000	10.00%	
Babi Holdings Pty Ltd ATF CLT Superfund	4,000,000	5.00%	
	12,000,000	15.00%	
Advate a Redistre a Redistre	0.000.000	44 4401	
Adaptive Radiation Pty Ltd	8,888,888	11.11%	
Sequential Investments Pty Ltd	1,600,000	2.00%	
	10,488,888	13.11%	



(2)

Name of shareholder	Mode of Acuisition	Price	Total Shares
Ruminate Investments Pty Ltd	Transferred	\$0.00003each	15,800,000
Abiogenesis Pty Ltd	Transferred	\$0.00003each	15,600,000
Adaptive Radiation Pty Ltd	Transferred	\$0.00003each	8,888,888
Agparaskevi Pty Ltd ATF Agparaskevi Trust	Allotted	\$0.00003each	8,000,000
Life Science Investments Pty Ltd ATF Life Science Super Fund	Transferred	\$0.00003each	6,000,000
Zero Hedge Investments Pty Ltd ATF Zero Hedge Investments Trust	Allotted	\$0.00003each	5,550,000
TTS Two Investments Pty Ltd	Allotted	\$0.00003each	4,500,000
Biotechnology Holdings Pty Ltd ATF Biotechnology Trust	Allotted	\$0.00003each	4,261,112
Babi Holdings Pty Ltd ATF CLT Superfund	Transferred	\$0.00003each	4,000,000
Mobery Pty Ltd	Allotted	\$0.00003each	1,600,000
Sequential Investments Pty Ltd	Transferred	\$0.00003each	1,600,000
Harry & Patricia Kouros ATF Kouros Superfund	Transferred	\$0.00003each	1,250,000
Ecapital Investments (No. 1) Pty Ltd	Allotted	\$0.00003each	800,000
Colin J. Odams Pty Ltd ATF Rangoon Trust	Transferred	\$0.00003each	750,000
Daniel & Sally Morato ATF Morato Family Superfund	Transferred	\$0.00003each	600,000
A & P Capital Pty Ltd	Transferred	\$0.00003each	400,000
PCS Investments Pty Ltd ATF PCS Investments Unit Trust	Transferred	\$0.00003each	250,000
Beale AM & AM	Tranbsferred	\$0.00003each	150,000

3. Securities

The securities to be listed will be comprised of:

- 80,000,000 Existing Ordinary Shares (100% of issued capital)
- 32,500,000 New Ordinary Shares under the Prospectus (at maximum or subject to subscription) at \$0.20 per share

4. History & Nature of Business



IQX Ltd is a new business (incorporated on 6th February 2012) with limited trading history. IQX Ltd is an investment company focused on investment in listed and unlisted entities in the Life Science sector. Further details about the Company operations and outlined in the enclosed Prospectus.

5. Summary of Earnings

IQX Ltd is a new business with limited trading history. No material earnings have yet been produced..A summary of the earnings is below:

ITEM	FY2011	FY2012	31-03-2013
Revenue		9,875	41,921
Net Profit Before Int, Dep,Tax	n/a	(154,476)	
Interest Expense	n/a	0	(39,285)
Depreciation Expense	n/a	135	6,637
Tax Expense	n/a	(40,542)	44,697
Net Profit	n/a	(114,639)	(77,345)

6. Tabulation of Balance Sheet

ITEM	FY2011	FY2012	31-03-2013
Current Assets	N/a	1,227,258	598,492
Non Current Assets	n/a	44,438	97,703
Non Current Liabilities	n/a	1,384,335	1,227,979
Net Assets		(112,639)	(531,784)

7. Employees

At the moment there are 7 regular employees which include:

- 4 Non-Executive Directors
- 1 Executive Director
- 2 Senior Management

8. Child Entities

IQX Investment Services Pty Ltd is a fully owned subsidiary of IQX Ltd. IQX Investment Services Pty Ltd is intended to act as the holding company for potential licenses the Company may be granted by ASIC in the future. 1 ordinary share has been issued to IQX Ltd.

9. Dividend Record



No dividends have been paid.

10. Properties

Location: Level 3, 222 Clarence St. Sydney, NSW 2000

Office Area: Approx. 200sqm

Office: 1

11. The company operates on a monthly sub - lease

N/A

12. Management

Mr Kosmas Dimirtou

17 Campbell St, Northmead, NSW 2152
Bachelor Commerce Laws, Diploma of Legal Practice (Tax)
Non-Executive Chairman

Kosmas is a Senior Tax Manager to the MLC NAB Wealth asset management Group. Over the last 6 years Kosmas has advised NAB wealth on both domestic and international acquisitions and investment product tax structuring issues. During the 6 years prior to joining NAB, Kosmas was a tax lawyer at PriceWaterhouse Coopers (PwC) in the PwC Sydney legal and tax division. Kosmas also has experience as a client tax manager specialising in the financial services industry and advised clients such as Colonial, Bank of America, DB RREEF and Lumley. Kosmas is a member of the Financial Services Council tax expert working group which lobbies the government for tax law reform.

As well as performing Chairman duties, Kosmas regularly guides the Company with respect to maintaining a high standard of Corporate Governance, minimizing risk and key personnel introductions.

Mr Peter Simpson

10 Monomeath Avenue, Canterbury, VIC 3126 Master of Pharmacy, Bachelor of Pharmacy Non-Executive Director

Peter has over 35 years' experience in the pharmaceutical industry and has been involved in the development of pharmaceutical products for both the Australian and international markets. For 8 years he was the Research and Development Manager at David Bull Laboratories and oversaw the development and approval of numerous pharmaceutical products.

Peter held the position of Chief Executive Officer at Biota Holdings Ltd for 8 years. During this time he was responsible for the research and development of a first in-class antiviral drug for the treatment and prevention of influenza. The drug developed was Relenza which was subsequently licensed to Glaxo Limited and had global sales of over US\$1.9 billion from 2007 through to 2011.

Currently, Peter maintains his association within the biotechnology and pharmaceutical industries and has an interest in late stage clinical studies and the commercialisation of Australian biomedical innovations

and discoveries. Peter also has a keen interest in the fields of clinical immunology and cancer therapies.



Peter's experience will help the Investment Committee evaluate the most efficient drug development pathway and commercial potential of investments opportunities.

Mr Anthony Panoyan

29 Rowe St, Roseville Chase, NSW 2069 Bachelor of Economics, Adv. Dip in Business, RG 146 (Securities) Executive Director, Head of Corporate Analysis

Anthony has held a number of roles in the finance sector, worked with numerous businesses ranging from start-ups right through to ASX listed companies.

Anthony was an equity analyst at Fat Prophets (boutique equity research firm) where he was responsible for carrying out investment research and analysis on listed companies across numerous industries. He held a corporate advisory role at Martin Place Securities (stock broking firm) where he managed capital raising transactions and carried out research and analysis for his clients. Anthony has also held other related roles, which included a business financing consultant, advising SME's on their business financing strategies, and a business development manager for a media firm in the private equity space where he assisted listed and unlisted companies in their investor relations strategy.

Anthony is actively involved in the Company on a daily basis and undertakes research and analysis on potential investments, stakeholder management (investors, advisors, lawyers, PR) and produces Company and investor communication material and documentation.

Mr Alex Dimos

52 Edenholme Rd, Russell Lea, NSW 2046 Bachelor of Economics, Graduate Diploma in Financial Planning Non-Executive Director

Alex is a financial advisor with over 18 years' experience across several disciplines in the financial services industry. Alex commenced his career in 1995 with an ASX listed insurance company where he held various management roles that offered him exposure to underwriting, claims and business development. Alex left the insurance industry in the year 2000 to pursue his interest in equity and capital investment markets.

From 2001 to 2005, Alex assumed a role as a private client financial advisor for Econ Financial Services, specialising in high net wealth individuals and practising largely in the area of self-managed superannuation. Currently, Alex is a Director of Econ Financial Services. He is charged with the responsibility of developing and maintaining an extensive financial planning advisory business. Alex has extensive knowledge across a large range of financial instruments and aspects of compliance and corporate governance of which he will apply this experience as part of the Company's investment process.

Alex regularly guides the Company with respect compliance, corporate governance and investment direction.

Mr John Stratilas

24 Applecross Avenue, Castle Hill, NSW 2154 Non-Executive Director



John brings to the Board over 20 years of experience in operating a number of businesses. During this time he has established, operated and sold businesses predominantly in the area of retail. He also has experience in commercial property development and management.

John applies his experience in understanding business operations and people to the Company.

Mr Spiro Sakiris

167 Charles Street, Putney, NSW 2112
Bachelor of Business, Diploma of Law, Member Institute of Chartered Accountants Australia COO, CFO, Company Secretary

Spiro is a senior partner of Economos Chartered Accountants and has been instrumental in the development of the firm since 1990. He is a registered company auditor and tax agent. During his twenty nine

years' experience in the Chartered Accountancy profession he has been involved in the areas of business and corporate advisory, taxation, audit and business systems designs across many industries including health, manufacturing, wholesale and distributions, retailing and construction.

Spiro is the compliance officer of Econ Financial Services Pty Ltd [AFSL 293876] and is ASIC RG 146 Compliant.

Spiro runs the Company's operational functions and overseas the financial affairs of the Company. This includes: management of the team, engagement with key business partners and investors, implementation of business systems and processes, compliance and corporate governance management and due diligence.

13. Sponsors, Bankers Etc

(1)

Authorised Intermediary	Capital & Finance Pty Ltd	29 Australia St, Camperdown NSW 2050
Financial Advisor	Economos Pty Ltd	The Galeries Victoria, Level 1 500 George Street, Sydney NSW 2000
Underwriter	K S Capital Pty Ltd	Level 2, 22 Pitt St, Sydney NSW 2000
Nominated Advisor	IQ3corp Ltd	Level 3, 222 Clarence St, Sydney NSW 2000
Solicitors	TressCox Lawyers	Level 9, 469 La Trobe St, Melbourne VIC 3000
Share Registry	Boardroom Pty Ltd	Level 7, 207 Kent St, Sydney NSW 2000
Principal Banker	ANZ Bank	219 Church St, Parramatta NSW 2150



(2) Issuers Auditor

Fortunity Assurance Pty Ltd Tim Davidson, BBus, FCA, SSA, FTIA Erina Business Park, 155 The Entrance Road, Erina NSW 2250

14. Statement of Non-Compliance

This is to advise that IQX Limited complies with the necessary listing rules of the NSX and that no request has been forwarded for a waiver or modification to the listing rules.

15. Declaration

This statement is to declare that:

- (1) save as specified in the application letter, all the qualifications for *listing* set out in Chapter 3 of Section IIA of the *Listing Rules* have, in so far as applicable and required to be met and fulfilled prior to application, been met or fulfilled in relation to IQX Limited and the securities of IQX Limited the subject of the application;
- (2) all information required to be included in the *disclosure document* pursuant to Rule 4.8 and the *Corporations Act* are included as per the attached Prospectus.
- (3) there are no other facts bearing on IQX Limited's application for *listing* which, in IQX Limited's opinion, should be disclosed to the *Exchange*.

Please let us know the timetable and next step required

Regards

Spiro Sakiris Company Secretary